Any current/future new fundraising through debt or equity?

The company is being cautious about over-leveraging and does not plan to significantly increase debt for upcoming CAPEX requirements, particularly for the Saykha project. For certain new products like pre-mixes, the company has already taken additional debt, increasing it by about Rs. 25 to 30 crores for the Kullu project. No anticipated CAPEX-related debt is expected for new products like Vitamin K1 and vegan D3 as they will utilize existing multi-purpose plants. The company is monetizing land assets (e.g., Thane, Pune) to fund investments, aiming to avoid increasing debt levels. No specific

Any current/future capex/capital investment/strategic investment?

Saykha Project: Estimated total investment of Rs. 150 to Rs. 200 crores to be done in phases; currently delayed due to resource availability and strategic decisions (Page 13). Pre-mix Plant: Initiated as a brownfield project in Kullu; plant expected to be commissioned and commercialized by Q4 FY22 (Page 8 and 13). Multi-purpose Plant Expansion at Dahej: Capacity expansion completed; supports Vitamin D3 and upcoming products like K1 and vegan D3 without additional CAPEX for these products (Page 10 and 14). Cautious approach on new CAPEX to avoid over-leveraging; preference to monetize lan

Future growth expectations in sales/revenue/volumes?

The company expects about a 20%-25% increase in volumes from capacity expansions, particularly if fully utilized for Vitamin D3, which can significantly boost revenue. New product launches like vegan Vitamin D3 and Vitamin K1 are targeted within the next two quarters, which could further drive growth. The Saykha plant’s implementation is delayed but will provide additional capacity for new products and minerals, supporting future volume growth. The human nutrition segment has grown steadily, with a focus on expanding market share, indicating potential revenue increases in this segment.

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets an average EBITDA margin of around 20% over the next 4-5 years; current margins are volatile mainly due to animal feed segment fluctuations. If animal feed prices improve, margins could increase to 23-25% or even higher, as historically margins reached up to 37%. Volume guidance is not publicly given due to prudence, but capacity expansions could lead to a 20-25% increase in Vitamin D3 volumes, supporting revenue growth. New product launches like vegan Vitamin D3 and Vitamin K1 are expected within 1-2 quarters, potentially driving future revenue. Capital expenditure

Fermenta Biotech LtdQ4 FY22Pharmaceuticals & Biotechnology

Fermenta Biotech Ltd Q4 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹553P/E: 25.2Market Cap: ₹1.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

The company expects about a 20%-25% increase in volumes from capacity expansions, particularly if fully utilized for Vitamin D3, which can significantly boost revenue.
New product launches like vegan Vitamin D3 and Vitamin K1 are targeted within the next two quarters, which could further drive growth.
The Saykha plant’s implementation is delayed but will provide additional capacity for new products and minerals, supporting future volume growth.
The human nutrition segment has grown steadily, with a focus on expanding market share, indicating potential revenue increases in this segment.
Animal feed volumes and prices have been volatile and suppressed; a recovery could lead to improved margins and higher revenues, but this remains uncertain.
The management refrains from giving specific volume guidance due to market volatility but remains confident in achieving an average EBITDA margin of around 20% over 4-5 years, reflecting steady operational growth.

Margin guidance

Category 3

The company targets an average EBITDA margin of around 20% over the next 4-5 years; current margins are volatile mainly due to animal feed segment fluctuations.
If animal feed prices improve, margins could increase to 23-25% or even higher, as historically margins reached up to 37%.
Volume guidance is not publicly given due to prudence, but capacity expansions could lead to a 20-25% increase in Vitamin D3 volumes, supporting revenue growth.
New product launches like vegan Vitamin D3 and Vitamin K1 are expected within 1-2 quarters, potentially driving future revenue.
Capital expenditure is cautiously planned to avoid over-leverage; some debt (~Rs. 25-30 crores) has been taken for premix plant expansion.
Real estate monetization is underway to support funding without increasing debt significantly.
Overall, the company remains confident about steady earnings growth and profitability improvements in the medium term.

See what Fermenta Biotech Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company is being cautious about over-leveraging and does not plan to significantly increase debt for upcoming CAPEX requirements, particularly for the Saykha project.
For certain new products like pre-mixes, the company has already taken additional debt, increasing it by about Rs. 25 to 30 crores for the Kullu project.
No anticipated CAPEX-related debt is expected for new products like Vitamin K1 and vegan D3 as they will utilize existing multi-purpose plants.
The company is monetizing land assets (e.g., Thane, Pune) to fund investments, aiming to avoid increasing debt levels.
No specific mention of equity fundraising was indicated in the transcript.

Order book

The transcript does not provide explicit details about the current or expected order book or pending orders for Fermenta Biotech Limited. However, relevant insights include: - Q4 FY22 showed increased volumes in human Vitamin D3 (15% growth quarter-on-quarter) and decreased animal feed volumes (64% decline quarter-on-quarter), indicating ongoing demand dynamics. - The company has focused on catering to the increased Vitamin D3 human nutrition demand during the COVID period. - New product launches like vegan Vitamin D3 and Vitamin K1 are targeted within the next 2 quarters, potentially contributing to future orders. - The onboarding of new customers in the human nutrition segment suggests a growing order pipeline. - The German and US subsidiaries are gaining approvals and customers which will aid in increasing volumes and order inflow. - Pre-mixes plant in Kullu expected to be commercialized by Q4 FY22, indicating forthcoming order fulfillment capability. - No specific figures or direct commentary on the exact order book or backlog are mentioned.

See what Fermenta Biotech Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Saykha Project: Estimated total investment of Rs. 150 to Rs. 200 crores to be done in phases; currently delayed due to resource availability and strategic decisions (Page 13).
Pre-mix Plant: Initiated as a brownfield project in Kullu; plant expected to be commissioned and commercialized by Q4 FY22 (Page 8 and 13).
Multi-purpose Plant Expansion at Dahej: Capacity expansion completed; supports Vitamin D3 and upcoming products like K1 and vegan D3 without additional CAPEX for these products (Page 10 and 14).
Cautious approach on new CAPEX to avoid over-leveraging; preference to monetize land assets (Page 12, 13).
Thane Land: Developing through joint venture Mextech Properties, monetizing via development rights without upfront capital expenditure (Page 12).
No anticipated CAPEX for new products like K1 and vegan D3 initially, leveraging existing Dahej plant capacity (Page 13).
Debt increased by Rs. 25-30 crores for Kullu pre-mix plant; no significant additional debt planned currently (Page 12).

Track Fermenta Biotech Ltd — get its next earnings analysis in your feed

How does Fermenta Biotech Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisFermenta Biotech Ltd

Rev 3Mar 3

See where Fermenta Biotech Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Fermenta Biotech Ltd rank in Pharmaceuticals & Biotechnology?

Compare Fermenta Biotech Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY22) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Fermenta Biotech Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Fermenta Biotech Ltd Q4 FY22 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Fermenta Biotech Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Fermenta Biotech Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season